Antigenic Modulation as a Limiting Factor in the Treatment of B-Cell Lymphoma with Anti-Idiotype Antibody

  • M. J. Glennie
  • G. T. Stevenson
Part of the Methodological Surveys in Biochemistry and Analysis book series (MSBA, volume 15B)


In exploring antibody (Ab) approaches to the treatment of malignant disease, one major problem is antigenic modulation, which allows tumour cells confronted by Ab to avoid damage from effector systems such as complement through redistribution and internalization of immune complexes. Working with anti-idiotype (anti-Id) Ab directed against neoplastic B lymphocytes we describe how Ab derivatives which are univalent but retain an intact Fc region can avoid this problem. Progress in this work has led to the construction of chimaeric molecules in which univalent Fab’γ from Ab is linked by thioether bonds to normal immunoglobulin (Ig) of the species to undergo immunotherapy. Two such derivatives, FabIgG and FabFc which use IgG and Fcy respectively as effector partners of the Ab Fab’γ, appear superior to parent Ab in their ability to invoke complement and K cell killing of target lymphocytes. They also show promise of utilizing Fab’γ from any source including monoclonal reagents and, because they present homologous Ig, should prove minimally immunogenic and efficient recruiters of host effector systems.


Thioether Bond Univalent Derivative Peptic Digestion Antigenic Modulation Lymphoma Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Stevenson, G.T. & Stevenson, F.K. (1983) Springer Semin. Immunopathol. 6, 99–115.CrossRefGoogle Scholar
  2. 2.
    Boyse, E. A. & Old, L.J. (1969) Ann. Rev. Genet. 3, 269–290.CrossRefGoogle Scholar
  3. 3.
    Chatenoud, L. & Bach, J.F. (1984) Immunol. Today 5, 20–25.CrossRefGoogle Scholar
  4. 4.
    Gordon, J., Anderson, V.A. & Stevenson, G.T. (1982) J. Immunol. 192, 2763–2769.Google Scholar
  5. 5.
    Glennie, M.J. & Stevenson, G.T. (1982) Nature 295, 712–714.CrossRefGoogle Scholar
  6. 6.
    Stevenson, G.T., Cole, V.M., Summerton, J. & Watts, H.F. (1984) Med. Oncol. Tumor Pharmacother. 1, 275–278.Google Scholar
  7. 7.
    Stevenson, G.T., Eady, R.P., Hough, D.W., Jurd, R.D. & Stevenson, F.K. (1975) Immunology 28, 807–820.Google Scholar
  8. 8.
    Stevenson, F.K., Morris, D. & Stevenson, G.T. (1980) Irrrrrunology, 41, 313–321.Google Scholar
  9. 9.
    Köhler, G. & Milstein, C. (1975) Nature 256,495–497.CrossRefGoogle Scholar
  10. 10.
    Stevenson, F.K., Glennie, M.J., Johnston, D.M.M., Tutt, A.L. & Stevenson, G.T. (1984) Br. J. Cancer 50, 407–413.CrossRefGoogle Scholar
  11. 11.
    Stevenson, G.T., Glennie. M.J. & Gordon, J. (1982) UCLA Symp. Mol. Cell Biol. 24, 459–472.Google Scholar
  12. 12.
    Engvall, E. & Perlmann, P. (1972) J. ImmunoZ. 109, 129–135.Google Scholar
  13. 13.
    Capra, J.D. (1977) Fed Proc. 36, 204–206.Google Scholar
  14. 14.
    Stevenson, G.T., Elliott, E.V. & Stevenson, F.K. (1977) Fed. Proc. 36, 2268–2271.Google Scholar
  15. 15.
    Chatenoud, L., Baudrihaye, M.F., Kreis, H., Goldstein, G., Schindler, J. & Bach, J.F. (1982) Eur. J. Immunol. 12, 979–982.CrossRefGoogle Scholar
  16. 16.
    Stackpole, C.W., Jacobson, J.B. & Galuska, S. (1978) J. Immunol. 120,188–197.Google Scholar

Copyright information

© Plenum Press, New York 1985

Authors and Affiliations

  • M. J. Glennie
    • 1
  • G. T. Stevenson
    • 1
  1. 1.Lymphoma Research Unit Tenovus Research LaboratorySouthampton General HospitalSouthamptonUK

Personalised recommendations